

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Sanofi</u> <hr/> (Last) (First) (Middle) <u>54 RUE LA BOETIE</u> <hr/> (Street) <u>PARIS IO 75008</u> <hr/> (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>07/17/2019</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>Fulcrum Therapeutics, Inc. [ FULC ]</u> <hr/> <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b> <hr/> <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	--	---

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Series B Preferred Stock (par value, \$0.001)<sup>(1)</sup></u>	<u>(2)</u>	<u>(2)</u>	<u>Common Stock</u>	<u>464,285<sup>(2)</sup></u>	<u>(2)</u>	<u>I<sup>(1)</sup></u>	<u>Through its wholly-owned subsidiary, Aventis Inc.</u>

**Explanation of Responses:**

1. Sanofi is the beneficial owner of Series B Preferred Stock of the Issuer through its wholly owned subsidiary Aventis Inc.
2. The Series B Preferred Stock is convertible on a seven-for-one basis into the number of shares of Common Stock of the Issuer as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the initial public offering of the Issuer without payment or further consideration. . The shares have no expiration date.

**Remarks:**

/s/ Alexandra Roger, Head of  
Securities Law and Capital      07/17/2019  
Markets

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.